Document is current
Any future updates will be listed below
-
Authors
Withers, Henry G.
Figel, Sheila A.
Qiu, Jingxin
Ahluwalia, Manmeet Singh
Reardon, David
Abad, Ajay P.
Curry, William T.
Wong, Eric T.
Peereboom, David M.
Dhawan, Andrew
Liu, Song
Ciesielski, Michael J.
Fenstermaker, Robert A.
-
Funding
Funding for this research was provided by:
National Institutes of Health (U24CA274159)
Roswell Park Alliance Foundation
Mr. Philip H. Hubbell
Linda Scime Endowment
MimiVax Inc
- License Information
-
More Information
Article History
Received: 15 August 2025
Accepted: 26 September 2025
First Online: 9 October 2025
Declarations
:
: M.J.C., R.A.F. are patent holders, and have ownership interests in MimiVax, Inc., developer of SurVaxM. M.J.C., S.A.F. are employed by MimiVax, Inc. M.S.A. is a shareholder of MimiVax, Inc.
: The study adheres to the Declaration of Helsinki and received approval from the institutional review boards at each of the participating hospitals: Beth Israel Deaconess Medical Center, Cleveland Clinic, Dana-Farber Cancer Institute, Massachusetts General Hospital, and Roswell Park Comprehensive Cancer Center (I-259614). All participants signed an informed consent prior to participation in the study. The clinical trial is registered at ClinicalTrials.gov (NCT02455557). Only publicly available, deidentified data from the open-access data tier were utilized for TCGA analyses.
